10
Views
0
CrossRef citations to date
0
Altmetric
Original Articles

Certain Trace Metal Disorders in Urinary Bladder of Bilharzial Patients suffering Bladder Carcinoma

Pages 328-331 | Received 14 Jan 1991, Accepted 26 Feb 1991, Published online: 26 Aug 2008
 

Abstract

The objective of the present work is to investigate any possible role which could have been played by the long-term treatment with antimony as an antibilharzial drug, and the development of urinary bladder carcinoma in patients suffering bilharzial complications. The present work has been planned to investigate the concentration levels of copper, zinc and antimony in urinary bladder tissues sampled from normal, bilharzial and bladder cancer patients subjected to surgical intervention. Both atomic absorption spectrophotometry and neutron activation analysis have been utilized for elemental estimations. The data obtained showed significant increase in the concentration levels of the three investigated metals in bladder cancer tumours as compared with their control levels under either normal or cancer-free bilharzial complications. The results have been statistically evaluated and discussed in view of the relevant literature. It has been concluded that the contributing role of the antibilharzial antimonial treatment in development of urinary bladder cancer cases cannot be overlooked and awaits further investigation.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.